Skip to main content

Peer Review reports

From: Cost-utility analysis of palivizumab for preventing respiratory syncytial virus in preterm neonates and infants in Colombia

Original Submission
18 Jun 2023 Submitted Original manuscript
Resubmission - Version 2
Submitted Manuscript version 2
2 Oct 2023 Reviewed Reviewer Report
8 Oct 2023 Reviewed Reviewer Report
9 Nov 2023 Author responded Author comments - Jaime E. Ordóñez
Resubmission - Version 3
9 Nov 2023 Submitted Manuscript version 3
3 Dec 2023 Reviewed Reviewer Report
16 Dec 2023 Reviewed Reviewer Report
5 Mar 2024 Author responded Author comments - Jaime E. Ordóñez
Resubmission - Version 4
5 Mar 2024 Submitted Manuscript version 4
5 Mar 2024 Author responded Author comments - Jaime E. Ordóñez
Resubmission - Version 5
5 Mar 2024 Submitted Manuscript version 5
4 Apr 2024 Author responded Author comments - Jaime E. Ordóñez
Resubmission - Version 6
4 Apr 2024 Submitted Manuscript version 6
Publishing
7 Apr 2024 Editorially accepted
19 Apr 2024 Article published 10.1186/s12879-024-09300-5

You can find further information about peer review here.

Back to article page